#HVO hVIVO PLC – LOI signed for Phase 3 Whooping Cough trial January 27, 2025 – Posted in: hVIVO (HVO)

Highlights ·   hVIVO has been selected to conduct a large-scale Phase 3 human challenge trial (“HCT”) for ILiAD Biotechnologies’ lead Bordetella pertussis (whooping cough) vaccine candidate, BPZE1 ·    World’s first pivotal Phase 3 human challenge trial in Bordetella pertussis  ·    Expanding hVIVO’s human challenge model portfolio ·    Expected to be Company’s largest HCT to date ·    Trial expected to commence H2 2025   hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world…

Continue reading